NCT04246606 (GEFPICS IHC4) is a clinical trial of IHC4 score in Breast Neoplasm Female, sponsored by UNICANCER.

Who is sponsoring NCT04246606?

NCT04246606 is sponsored by UNICANCER.

What drugs are being tested in NCT04246606?

Interventions in NCT04246606: IHC4 score.

What condition does NCT04246606 study?

NCT04246606 studies Breast Neoplasm Female.

Is NCT04246606 still recruiting?

NCT04246606 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT04246606: GEFPICS IHC4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

Completed Last updated 18 November 2023

What this trial tests

trial testing IHC4 score in Breast Neoplasm Female in 155 participants. Completed in 1 November 2023.

Timeline

24 April 2020

Primary endpoint
30 September 2023

1 November 2023

Quick facts

Lead sponsor	UNICANCER
Status	Completed
Study type	OBSERVATIONAL
Enrollment	155
Start date	24 April 2020
Primary completion	30 September 2023
Estimated completion	1 November 2023
Sites	1 location across France

Drugs / interventions tested

IHC4 score

Conditions studied

Breast Neoplasm Female — all drugs for Breast Neoplasm Female →

Sponsor

UNICANCER — full company profile →

Who can join

18 and older, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective observational, multicentric study assessing the immunohistochemistry (IHC) based test IHC4 score in infiltrating early breast cancer: comparison of the score performed in local laboratory vs in a central laboratory and concordance with a molecular gold standard classifier (EndoPredict).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.
Xulu KR, Nweke EE, Augustine TN. · · 2023 · cited 7× · PMID 37662839 · DOI 10.3389/fgene.2023.1087432

Verify or expand the search:

Other recruiting trials for Breast Neoplasm Female

Currently open trials in the same condition.

NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting

Other UNICANCER trials

Trials by the same sponsor.

NCT07340619 — Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT07360834 — Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndr · NA · not yet recruiting
NCT07106632 — Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests · Phase 3 · not yet recruiting
NCT07294430 — Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate. · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04246606 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNICANCER
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04246606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing